Le risque hémorragique des nouveaux anticoagulants oraux

Garcia, 2010, The new oral anticoagulants, Blood, 115, 15, 10.1182/blood-2009-09-241851 Furie, 2008, Mechanisms of thrombus formation, N Engl J Med, 359, 938, 10.1056/NEJMra0801082 Schulman, 2009, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, 2342, 10.1056/NEJMoa0906598 Lassen, 2008, RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty, N Engl J Med, 358, 2776, 10.1056/NEJMoa076016 Eriksson, 2004, Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement:BISTRO I, J Thromb Haemost, 2, 1573, 10.1111/j.1538-7836.2004.00890.x Eriksson, 2005, A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial, J Thromb Haemost, 3, 103, 10.1111/j.1538-7836.2004.01100.x Eriksson B, Turpie AGG, Lassen MR, Kakkar AK, Gent M, on behalf of the RECORD1-4 investigators. Pooled Analysis of Four Rivaroxaban Studies: NSAIDs, ASA and Platelet Inhibitors. XXIIe Congress of the International Society on Thrombosis and Haemostasis, July 11-16, 2009.